Agreement between breast cancer risk estimation methods.
Agreement between breast cancer risk estimation methods.
复制标题
乳腺癌风险估计方法之间的协议。
DOI：
10.1093/jnci/88.18.1315
复制
发表时间：
1996
期刊：
影响因子：
--
通讯作者：
Breant,C
中科院分区：
文献类型：
--
作者：
McGuigan,KA;Ganz,PA;Breant,C
准确识别患乳腺癌的高风险妇女在研究和临床环境中都有重要的用途。识别高危人群研究化学预防药物需要一个可靠有效的风险预测模型（/）。针对高危人群使用化学预防药物减少了临床试验所需的样本量，提高了参与者的风险/收益比(2)。更具体的风险信息也有助于临床咨询，因为许多妇女高估了她们患乳腺癌的实际风险（3,4）。两种基于模型的个性化风险预测方法已提供用于研究和临床应用。第一个模型由Gail等人(5)开发（Gail模型），使用来自乳腺癌检测示范项目（BCDDP）的病例和对照受试者。Claus等人(6)建立的第二个模型（Claus模型）是从癌症和类固醇激素（CASH）研究的受试者中发展而来的。Gail模型的风险估计基于内源性雌激素暴露、家族史和临床风险指标（5,7,8）。克劳斯模型使用遗传模型，根据先前诊断为乳腺癌的一级和二级亲属的数量和诊断年龄，将风险制成表格。这些预测是基于
Accurate identification of women at high risk of developing breast cancer has important uses in both research and clinical settings. Identification of highrisk groups to study chemopreventive agents requires a reliable and valid risk projection model (/). Targeting chemopreventive agents to those at highest risk decreases the required sample size for clinical trials and improves the risk/benefit ratio for participants (2). Clinical counseling is also facilitated by more specific risk information, because many women overestimate their actual risk of breast cancer (3, 4).Two model-based approaches to individualized risk prediction have been offered for use in research and clinical applications. The first model was developed by Gail et al.(5)(Gail model) using case and control subjects from the Breast Cancer Detection Demonstration Project (BCDDP). The second model, by Claus et al.(6)(Claus model), was developed from subjects in the Cancer and Steroid Hormone (CASH) Study. Risk estimation from the Gail model is based on indicators of endogenous estrogen exposure, family history, and clinical risk (5, 7, 8). The Claus model uses genetic modeling to tabulate risk on the basis of the number and age at diagnosis of first-and second-degree relatives previously diagnosed with breast cancer. These predictions are based on